IL161573A0 - [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS - Google Patents

[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Info

Publication number
IL161573A0
IL161573A0 IL16157302A IL16157302A IL161573A0 IL 161573 A0 IL161573 A0 IL 161573A0 IL 16157302 A IL16157302 A IL 16157302A IL 16157302 A IL16157302 A IL 16157302A IL 161573 A0 IL161573 A0 IL 161573A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
triazole
bicyclic
triazole bicyclic
Prior art date
Application number
IL16157302A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL161573A0 publication Critical patent/IL161573A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16157302A 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS IL161573A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
PCT/US2002/037915 WO2003048163A1 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
IL161573A0 true IL161573A0 (en) 2004-09-27

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16157302A IL161573A0 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Country Status (18)

Country Link
US (2) US6875772B2 (OSRAM)
EP (1) EP1453836B1 (OSRAM)
JP (2) JP4429724B2 (OSRAM)
KR (1) KR20050044600A (OSRAM)
CN (1) CN1688581A (OSRAM)
AR (1) AR037681A1 (OSRAM)
AT (1) ATE358130T1 (OSRAM)
AU (1) AU2002352933A1 (OSRAM)
CA (1) CA2468658C (OSRAM)
DE (1) DE60219196T2 (OSRAM)
ES (1) ES2283625T3 (OSRAM)
HU (1) HUP0402324A3 (OSRAM)
IL (1) IL161573A0 (OSRAM)
MX (1) MXPA04005158A (OSRAM)
PE (1) PE20030653A1 (OSRAM)
TW (1) TW200300689A (OSRAM)
WO (1) WO2003048163A1 (OSRAM)
ZA (1) ZA200404168B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2002352933A1 (en) * 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists
NZ535169A (en) * 2002-03-12 2006-03-31 Wyeth Corp Process for making chiral 1,4-disubstituted piperazines
CA2500228A1 (en) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]-triazolo[1,5-c]pyrimidine derivative
NZ540493A (en) 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
EP1615930A2 (en) 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
US20090124663A1 (en) * 2005-06-08 2009-05-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200803856A (en) 2005-09-02 2008-01-16 Mount Cook Biosciences Inc Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
EP3814355B1 (en) 2018-06-26 2025-12-24 Zhejiang Vimgreen Pharmaceuticals, Ltd Triazolotriazine derivatives as a2a receptor antagonists
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
US20230048888A1 (en) * 2019-12-26 2023-02-16 Zhejiang Vimgreen Pharmaceuticals, Ltd. Use of triazolotriazine derivative in treatment of diseases
JP7646873B2 (ja) * 2021-04-23 2025-03-17 チョン クン ダン ファーマシューティカル コーポレイション アデノシンＡ２ａ受容体アンタゴニストとしての化合物およびこれを含む薬学的組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) * 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
HUP0103921A3 (en) * 1998-09-22 2002-12-28 Kyowa Hakko Kogyo Kk [1,2,4]triazolo[1,5-c]pyrimidine derivatives and pharmaceutical compositions thereof
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
MXPA02011625A (es) 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
AR037243A1 (es) * 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
AU2002352933A1 (en) * 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
US7078408B2 (en) 2006-07-18
CA2468658A1 (en) 2003-06-12
AR037681A1 (es) 2004-12-01
EP1453836B1 (en) 2007-03-28
AU2002352933A1 (en) 2003-06-17
CA2468658C (en) 2009-04-14
HUP0402324A2 (hu) 2005-02-28
WO2003048163A1 (en) 2003-06-12
KR20050044600A (ko) 2005-05-12
US20050113380A1 (en) 2005-05-26
US20030191130A1 (en) 2003-10-09
PE20030653A1 (es) 2003-08-04
DE60219196T2 (de) 2008-01-03
US6875772B2 (en) 2005-04-05
MXPA04005158A (es) 2004-08-11
ES2283625T3 (es) 2007-11-01
HK1064097A1 (en) 2005-01-21
ZA200404168B (en) 2005-09-02
ATE358130T1 (de) 2007-04-15
JP2010018634A (ja) 2010-01-28
TW200300689A (en) 2003-06-16
JP2005511697A (ja) 2005-04-28
DE60219196D1 (de) 2007-05-10
CN1688581A (zh) 2005-10-26
EP1453836A1 (en) 2004-09-08
HUP0402324A3 (en) 2008-09-29
JP4429724B2 (ja) 2010-03-10

Similar Documents

Publication Publication Date Title
IL161573A0 (en) [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
AU6808901A (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
PL353969A1 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
IL147198A0 (en) N-pyrazole a2a receptor agonists
IL147195A0 (en) C-pyrazole a2a receptor agonists
AU5640199A (en) 4-quinolinemethanol derivatives as purine receptor antagonists (i)
SI1622912T1 (sl) 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti
SG80041A1 (en) Muscarinic receptor antagonists
PL377053A1 (pl) Związki 2-aminokarbonylo-chinoliny jako antagonisty receptora płytkowego difosforanu adenozyny
HUP0400530A3 (en) Condensed purine derivatives as a1 adenosine receptor antagonists
PL353366A1 (en) Pyrazolo[4,3-d]pyrimidines
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
IL162444A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU4980999A (en) A3 adenosine receptor antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
GB0101223D0 (en) Histamine receptor antagonists
AU2574801A (en) Selective iGLUR5 receptor antagonists
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B